Our Network of Consultants

I am a bioprocess development scientist with over eight years of industrial experience in downstream process development, manufacturing sciences and technology (MSAT), technology transfer, protein sciences, and GMP biomanufacturing. My expertise spans the complete biologics development lifecycle, from early discovery and process development to process characterization, scale-up, manufacturing support, process validation, and commercial technology transfer.

Throughout my career, I have contributed to the development of more than 60 biologic molecules across diverse therapeutic modalities, including monoclonal antibodies, bispecific antibodies, fusion proteins, growth factors, biosimilars, vaccines, viral vectors, plasmid DNA, gene therapy products, and plant-derived biologics. I have extensive experience in designing and optimizing scalable downstream purification processes using affinity, ion exchange, mixed-mode, hydrophobic interaction, reverse-phase, and size-exclusion chromatography, along with tangential flow filtration (TFF), ultrafiltration/diafiltration (UF/DF), and membrane-based separation technologies.

My professional experience includes leadership and technical roles at Zatloukal Innovations GmbH (Austria), Aurigene Discovery Biologics (Dr. Reddy’s Laboratories), CuraTeQ Biologics, Biocon Biologics, Mynvax, Stelis Biopharma, Appasamy Biopharma, and Tallinn University of Technology. These roles have provided me with broad expertise in recombinant protein expression, analytical characterization, structural biology, CMC development, process troubleshooting, quality systems, regulatory compliance, and cross-functional project leadership.

I have successfully supported technology transfer, manufacturing readiness, engineering and GMP manufacturing campaigns, process optimization, and continuous improvement initiatives in both development and commercial manufacturing environments. My approach combines scientific rigor with practical manufacturing expertise to develop robust, scalable, and cost-effective bioprocesses that accelerate product development and commercialization.

I currently lead downstream bioprocess development and quality control activities for next-generation plant-derived biologics. I am passionate about translating innovative scientific discoveries into scalable manufacturing solutions and supporting biotechnology organizations through technical leadership, strategic process development, and successful technology transfer.

Cell and gene therapy R&D lead with experience supporting translational biotechnology projects from early-stage experimental design through to preclinical strategy and grant development. Skilled in designing and managing complex research programmes, analysing scientific data, and communicating technical concepts to both scientific and commercial stakeholders.

Experienced across biotech innovation, scientific writing, literature analysis, and cross-functional project coordination, with a particular interest in emerging therapeutic technologies and translational research. Available for consulting projects involving experimental planning, technical review, grant writing, data interpretation, and biotech R&D strategy.

Industry-focused structural biologist, team leader, and consultant with over 14 years of experience across biotech startups, pharma, and world-class academic institutes (EMBL, University of Bristol). Proven expertise in end-to-end vaccine and biologics development, with a specialization in protein engineering, molecular design, advanced vaccine platforms (VLPs), and multiprotein complexes. Strong track record of translating complex structural biology into scalable, deployable products, bridging the gap between R&D discovery and clinical manufacturing (CMC, USP/DSP, and CDMO tech transfer). Offers high-impact technical due diligence and strategic advisory to de-risk early-stage pipelines and accelerate time-to-market.

I work with life sciences and biotech companies as a fractional CFO and finance director. With 16 years of experience across EMEA operations including financial director and supply chain finance roles within global life sciences businesses, I bring enterprise level finance capability to growing companies without the cost of a full time hire.
I help founders and leadership teams with investor ready financial reporting, budgeting and forecasting, audit readiness, cash flow management, board reporting, EMEA multi entity operations and UK subsidiary setup for overseas businesses.
I am dual qualified ACA and FCCA with an Executive MBA from London Business School. I work with companies typically between £5m and £50m revenue at key growth and funding stages.

My area of study is the intersection of clinical neuroscience, translational pharmacology, and computational biomarker discovery. I am a PhD candidate investigating how glymphatic and meningeal–lymphatic pathways relate to neuroinflammation in humans. I focus on immune-cell phenotyping and cell-free markers that may index inflammatory activity and neurodegenerative trajectories. Alongside sampling development, I contribute to assay and workflow optimisation for mass-spectrometry-ready proteomics, with an emphasis on automation, quality control, and reproducibility.

My pharmacology and drug-safety foundation was built through an MRes in Biological Science and Translational Medicine. I examined dose- and time-dependent paracetamol-induced kidney injury in renal cell models, differentiating apoptotic and necrotic mechanisms and linking experimental readouts to clinically relevant nephrotoxicity questions. I completed a systematic review on cilastatin as a renoprotective strategy and critically evaluated in vitro acute kidney injury models for translational validity. I also gained ward-level exposure as a Clinical Research Associate in nephrology, aligning laboratory findings with real-world clinical pathways and multidisciplinary decision-making.

From an industry and communications perspective, I have experience in medical affairs-adjacent work, including market analysis to support launch planning in an ophthalmic pharmaceutical company and the development of compliant training materials with medical teams. I have delivered conference and hospital presentations, tailoring complex findings to both clinical and public audiences, and I have completed structured projects on European compliance frameworks, which underpins my approach to regulatorily aware medical writing.

Computationally, I build end-to-end machine-learning workflows in Python and R for noisy, high-dimensional datasets, particularly proteomics and multimodal clinical data. My toolkit spans supervised learning, unsupervised clustering, and dimensionality reduction.

Overall, my expertise is translating complex biomedical and quantitative evidence into actionable deliverables, supported by an MBA in Clinical Leadership and a strong biochemistry foundation, including earlier research on TEX12 expression in somatic and cancer models.

I am a freelance Quality Assurance consultant/auditor with 14 years experience in the Pharmaceutical industry and I offer QMS development/support and Lead Auditor services for Life Science and Biotech organisations. My most recent role prior to freelance work was as the Global Supplier Quality Manager for a Biotech organisation where I was responsible for management of over 100 suppliers, with oversight of a small team of auditors and conduct of audits as a Lead Auditor in support for Clinical operations, as well as development/support for the site QMS.

With over 25 years of leadership in the Life Sciences and Diagnostics market, I have built a proven track record of blending entrepreneurial vision with strategic business management expertise. Drawing from a wealth of experience across Business Development, R&D, Marketing, Sales, and Manufacturing, I have developed a deep technical foundation that drives a passion for revenue growth, market share expansion, and profit performance enhancement.

My leadership is defined by a commitment to innovation and a solution-oriented mindset, consistently helping businesses navigate complex challenges while fostering sustainable, high-impact partnerships across global markets.

Key Strengths:
• Building and scaling international distribution and sales channels
• Motivating and guiding teams to accelerate revenue growth
• Driving success in OEM and B2B sales strategies
• Leading contract negotiations, technology transactions, and licensing agreements
• Spearheading global business development across EMEA, APAC, LATAM, and Africa

By leveraging my expertise, global connections, and industry insights, companies can optimize their distribution networks, ensuring measurable results and maximizing revenue. With a focus on fine-tuning distribution strategies, together we can deliver sustainable growth across key regions.

With a distinguished background, which includes a PhD and an eMBA, I seamlessly integrate scientific and technical expertise with a profound understanding of global business strategy in chemistry for the biology, assay development and detection methods.

Senior technical expertise on antibodies and immunoassays

With a thorough background of molecular cell biology and biochemistry, I have accrued multi-disciplinary knowledge and experience while working in both academic and commercial environments with an emphasis on antibodies and immunoassays. During my CSO appointment at an antibody manufacturer, I have gained global recognition on my knowledge of commercial antibodies and their validation through meetings and publications. During my time involving drugs discovery I have developed several assays and filed for patents. I have tutored and trained assistants to very high standard, and many of them have moved on the career ladder since then. After I have written SOPs in a GLP-audited CRO and many technical and managerial SOPs for a fast-growing research antibody manufacturer, my focus has been on protein biomarkers and antibody validation to industrial standard. This focus led to a thorough understanding of etiologies at protein level and of diagnostics and medical interventions. My understanding of physical, chemical, and pharmacological principles made me ready to move on as an independent consultant to aid antibody manufacturers and in vitro diagnostics industries. My interest in strategic planning has helped me thinking creatively thus providing valuable inspirations to move biotech/pharma companies forward.
Based on the above, I was in the opportunity to set up my own company to introduce a long sought after quality standard for commercial tool antibodies. This concept may ultimately also work for the early discovery of candidate therapeutic antibodies.
My expertise is now available to assist in technical or strategic hurdles when complementary experience is required. When assistance is needed for a start-up or for a well-established company, confidentiality is guaranteed, and NDAs can be exchanged when required.